Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

MRVI Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds MRVI Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Maravai LifeSciences Holdings, Inc.

MRVI

SAN DIEGO, CA / ACCESS Newswire / March 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) securities between August 7, 2024 and February 24, 2025. Maravai is a life sciences company that provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating Allegations that Maravai LifeSciences Holdings, Inc. (MRVI) Intentionally Recorded Unearned Revenues

According to the complaint, during the class period, defendants failed to disclose to investors that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4) that, as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On February 25, 2025, Maravai revealed it identified an error in revenue recognition and "a material weakness in its internal controls over revenue recognition. On this news, the price of the Company's stock fell over 21% to close at $3.14 per share on February 25, 2025.

What Now: You may be eligible to participate in the class action against Maravai LifeSciences Holdings, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 5, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.

To be notified if a class action against Maravai LifeSciences Holdings, Inc. or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contact:
Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

SOURCE: Robbins LLP



View the original press release on ACCESS Newswire